Skip to content

Released May 12, 2023, after the close

10-Q filed May 15, 2023, 45 days after period end · 0000950170-23-021976

Q1 2023 · 10-Q
Revenue$12.67M+114.9% vs Q1 2022+46.8% vs Q4 2022
Net Income-$50.05MN/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.85N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$42,237,000N/M
Operating Cash Flow-$60,991,000N/M
Margins · derived
Operating margin-333.3%+330.3 pt vs Q1 2022
Net margin-394.9%+268.3 pt vs Q1 2022

What the release said

The release

Same quarter

MetricQ1 2023Q1 2022Q1 2021Q1 2020
Revenue$12.67M$5.90M$14.66M$7.15M
Net Income-$50.05M-$39.11M-$30.36M-$19.60M
EPS Diluted-$0.85-$0.84-$0.66-$0.84

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR